Page 344 - Haematologica Vol. 109 - July 2024

LETTER TO THE EDITOR
Medical College; 2Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; 3Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College and 4State Key Laboratory of Common Mechanism Research for Major Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
*KNS and YJG contributed equally as first authors.
Correspondence:
J. LI - lijian@pumch.cn
https://doi.org/10.3324/haematol.2024.285145
Received: February 3, 2024. Accepted: March 15, 2024. Early view: March 28, 2024.
©2024 Ferrata Storti Foundation Published under a CC BY-NC license
References
1. Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420-3427.
2. Palladini G, Schonland S, Merlini G, et al. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018. Blood Cancer J. 2023;13(1):19.
3. Shen KN, Zhang CL, Tian Z, et al. Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study. Amyloid. 2019;26(2):66-73.
4. Kastritis E, Palladini G, Minnema MC, et al. Daratumumab- based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385(1):46-58.
5. Minnema MC, Dispenzieri A, Merlini G, et al. Outcomes by cardiac stage in patients with newly diagnosed AL amyloidosis: phase 3 ANDROMEDA trial. JACC CardioOncol. 2022;4(4):474-487.
6. Edwards CV, Rao N, Bhutani D, et al. Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis. Blood. 2021;138(25):2632-2641.
7. Shen KN, Fu WJ, Wu Y, et al. Doxycycline combined with bortezomib-cyclophosphamide-dexamethasone chemotherapy for newly diagnosed cardiac light-chain amyloidosis: a multicenter randomized controlled trial. Circulation. 2022;145(1):8-17.
8. Kastritis E, Minnema M, Dimopoulos MA, et al. Efficacy and safety of daratumumab monotherapy in newly diagnosed patients with stage 3B light chain amyloidosis: a phase 2 study
Disclosures
No conflicts of interest to disclose.
Contributions
KNS and JL contributed to the concept and design of the study. KNS, YJG, LC, LZ, XXC, ZT, YNW, DBZ and JL collected data, KNS and YJG further contributed to data analysis and drafted the manuscript. All authors contributed to data interpretation, critically reviewed the manuscript and approved the final version.
Funding
This work was supported by the National Natural Science Foundation of China (grant no. 82200230, to KNS); the National High Level Hospital Clinical Research Funding (grant no. 2022-PUMCH-A-260, to KNS); the CAMS Innovation Fund for Medical Sciences (grant no. 2021- I2M-1-019, to JL); and the National High Level Hospital Clinical Research Funding (grant no. 2022-PUMCH-C-051, to JL); and funding from Xi’an Janssen Pharmaceutical Ltd., Beijing, China.
Data-sharing statement
The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.
by the European Myeloma Network. Blood. 2023;142(Suppl 1):539. 9. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for
response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541-4549.
10. Palladini G, Schonland SO, Sanchorawala V, et al. Clarification on the definition of complete haematologic response in light- chain (AL) amyloidosis. Amyloid. 2021;28(1):1-2.
11. Muchtar E, Dispenzieri A, Wisniowski B, et al. Graded cardiac response criteria for patients with systemic light chain amyloidosis. J Clin Oncol. 2023;41(7):1393-1403.
12. Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124(15):2325-2332.
13. Gao YJ, Shen KN, Miao HL, et al. A retrospective study of ultrahigh-risk (Mayo 2004 stage IIIb) AL amyloidosis and identification of predictors related to extremely early death. Leuk Lymphoma. 2022;63(7):1758-1761.
14. Chakraborty R, Rosenbaum C, Kaur G, et al. First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara-VCD front-line therapy. Br J Haematol. 2023;201(5):913-916.
15. Oubari S, Hegenbart U, Schoder R, et al. Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival. Haematologica. 2024;109(1):220-230.
Haematologica | 109 July 2024
2358